Less than $10/month! Get more Watchlists, Portfolios, Custom Views and Chart Templates with Barchart Plus. FREE 30 Day Trial
or

Cardiff Oncology Inc (CRDF)

Cardiff Oncology Inc (CRDF)
N/A x N/A N/A x N/A
Post-market by (Cboe BZX)
2.75 -0.12 (-4.18%) 04/04/25 [NASDAQ]
N/A x N/A N/A x N/A
Post-market 2.81 +0.06 (+2.18%) 19:49 ET
Quote Overview for Fri, Apr 4th, 2025
Watch
    Add or delete the symbol from one or more Watchlists.
Day Low
2.62
Day High
2.82
Open 2.80
Previous Close 2.87 2.87
Volume 1,607,100 1,607,100
Avg Vol 1,205,870 1,205,870
Stochastic %K 5.22% 5.22%
Weighted Alpha -64.11 -64.11
5-Day Change -0.54 (-16.41%) -0.54 (-16.41%)
52-Week Range 2.01 - 6.35 2.01 - 6.35
  • 1D
  • 5D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
  • MAX
Full Chart
  • OHLC Bars
  • Colored OHLC Bars
  • HLC Bars
  • Candlestick Hollow
  • Candlestick Open-to-Close
  • Candlestick Close-to-Close
  • Heikin-Ashi
  • Line Chart
  • Area Chart
  • Renko
  • Column
  • Baseline
  • Line Break
  • Range
  • Kagi
  • Point And Figure
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 182,941
  • Shares Outstanding, K 66,524
  • Annual Sales, $ 680 K
  • Annual Income, $ -45,430 K
  • EBIT $ -49 M
  • EBITDA $ -49 M
  • 60-Month Beta 1.74
  • Price/Sales 279.54
  • Price/Cash Flow N/A
  • Price/Book 1.62

Options Overview Details

View History
  • Implied Volatility 362.63% ( +248.08%)
  • Historical Volatility 90.91%
  • IV Percentile 98%
  • IV Rank 55.67%
  • IV High 628.39% on 09/18/24
  • IV Low 28.90% on 05/22/24
  • Put/Call Vol Ratio 0.04
  • Today's Volume 464
  • Volume Avg (30-Day) 490
  • Put/Call OI Ratio 0.14
  • Today's Open Interest 26,616
  • Open Int (30-Day) 26,316

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/25
See More
  • Average Estimate -0.20
  • Number of Estimates 4
  • High Estimate -0.18
  • Low Estimate -0.23
  • Prior Year -0.22
  • Growth Rate Est. (year over year) +9.09%

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.62 +4.96%
on 04/04/25
Period Open: 3.73
4.42 -37.78%
on 03/12/25
-0.98 (-26.37%)
since 03/04/25
3-Month
2.62 +4.96%
on 04/04/25
Period Open: 4.70
4.99 -44.89%
on 02/21/25
-1.95 (-41.49%)
since 01/03/25
52-Week
2.01 +36.82%
on 08/05/24
Period Open: 5.67
6.35 -56.69%
on 04/05/24
-2.92 (-51.50%)
since 04/04/24

Most Recent Stories

More News
Why the Global Cancer Market Could Surpass $900 Billion--And the Stocks Leading the Charge

/CNW/ -- As the global cancer crisis intensifies, the demand for breakthrough treatments is reaching new heights. Statista data projects a 20% rise in annual...

ONCY : 0.4952 (-3.28%)
EXEL : 34.57 (-5.75%)
ONC.TO : 0.70 (-1.41%)
ALXO : 0.5159 (-3.23%)
CRDF : 2.75 (-4.18%)
VSTM : 5.16 (-9.47%)
Cardiff Oncology Reports Fourth Quarter and Full Year 2024 Results and Provides Business Update

CRDF : 2.75 (-4.18%)
Cardiff Oncology to Present at Upcoming Investor Conferences

CRDF : 2.75 (-4.18%)
Cardiff Oncology to Report Fourth Quarter 2024 Results and Provide Business Update

CRDF : 2.75 (-4.18%)
Achievements and Progress Heading into 2025 for Oncology Treatments and Therapies Fuel an Optimistic Outlook

EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NYSE:GSK),(NASDAQ:AZN),(NYSE:ABBV),(NASDAQ:CRDF) EQNX::TICKER_END

ONCY : 0.4952 (-3.28%)
AZN : 68.46 (-7.39%)
ABBV : 186.96 (-7.28%)
ONC.TO : 0.70 (-1.41%)
GSK : 36.53 (-6.36%)
CRDF : 2.75 (-4.18%)
Oncology Advancements Accelerate Amid Rising Early-Onset Cancer Diagnoses

EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NASDAQ:CRDF),(NASDAQ:PSNL),(NASDAQ:TEM),(NASDAQ:CKPT) EQNX::TICKER_END

ONCY : 0.4952 (-3.28%)
CKPT : 4.01 (-0.74%)
PSNL : 3.11 (-5.76%)
ONC.TO : 0.70 (-1.41%)
TEM : 42.58 (-7.78%)
CRDF : 2.75 (-4.18%)
Oncology Advancements Accelerate Amid Rising Early-Onset Cancer Diagnoses

/CNW/ -- USA News Group News Commentary – The American Cancer Society has published its Advances in Oncology – 2024 Research Highlights, underscoring major...

ONCY : 0.4952 (-3.28%)
CKPT : 4.01 (-0.74%)
PSNL : 3.11 (-5.76%)
ONC.TO : 0.70 (-1.41%)
TEM : 42.58 (-7.78%)
CRDF : 2.75 (-4.18%)
Cancer Care Disruptions Highlight Growing Demand for Innovative Oncology Treatments

/CNW/ -- USA News Group News Commentary – The American Cancer Society recently released its Advances in Oncology – 2024 Research Highlights report that...

ONCY : 0.4952 (-3.28%)
CKPT : 4.01 (-0.74%)
LLY : 738.21 (-6.45%)
ONC.TO : 0.70 (-1.41%)
OSTX : 1.4000 (-9.09%)
CRDF : 2.75 (-4.18%)
Cardiff Oncology Reports Promising Initial Results from Phase 2 CRDF-004 Trial of Onvansertib in RAS-Mutated mCRC

Cardiff Oncology's Phase 2 trial shows onvansertib combined with SoC yields 64% ORR in RAS-mut mCRC patients.Quiver AI SummaryCardiff Oncology, Inc. announced positive preliminary results from its Phase...

CRDF : 2.75 (-4.18%)
Cardiff Oncology Prices Oversubscribed $40 Million Underwritten Registered Direct Offering

CRDF : 2.75 (-4.18%)
Cardiff Oncology Announces Positive Initial Data from First-line RAS-mutated mCRC Clinical Trial

CRDF : 2.75 (-4.18%)
Cardiff Oncology Announces New Patent with Claims for the Use of Onvansertib in Treating KRAS mutated mCRC

CRDF : 2.75 (-4.18%)
Cardiff Oncology: Q3 Earnings Snapshot

Cardiff Oncology: Q3 Earnings Snapshot

CRDF : 2.75 (-4.18%)
Cardiff Oncology Reports Third Quarter 2024 Results and Provides Business Update

CRDF : 2.75 (-4.18%)
Cardiff Oncology Announces Journal of Clinical Oncology Publication of Data from Phase 2 Trial in Second-line KRAS Mutant mCRC

CRDF : 2.75 (-4.18%)
Cardiff Oncology: Q2 Earnings Snapshot

Cardiff Oncology: Q2 Earnings Snapshot

CRDF : 2.75 (-4.18%)
Fight Against Pancreatic Cancer Ramps Up as Market Size Revenues Expected to Exceed $36 Billion by 2036

EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NASDAQ:ZLAB),(NASDAQ:NTBL),(NASDAQ:CRDF),(NYSE:JNJ) EQNX::TICKER_END

ONCY : 0.4952 (-3.28%)
ONC.TO : 0.70 (-1.41%)
ZLAB : 31.77 (-13.41%)
NTBL : 0.2479 (-27.68%)
CRDF : 2.75 (-4.18%)
JNJ : 153.24 (-4.12%)
Rising Number of Studies to Develop Novel Therapies For Pancreatic Ductal Adenocarcinoma (PDAC) Intensely Increasing

EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NASDAQ:CRDF),(NYSE:LLY),(NYSE:ABBV),(NASDAQ:LIPO) EQNX::TICKER_END

ONCY : 0.4952 (-3.28%)
ONC.TO : 0.70 (-1.41%)
CRDF : 2.75 (-4.18%)
LLY : 738.21 (-6.45%)
ABBV : 186.96 (-7.28%)
LIPO : 2.36 (-5.50%)
Nasdaq Futures Climb as Bond Yields Retreat From Decade Highs, Micron Earnings on Tap

December Nasdaq 100 E-Mini futures (NQZ23) are trending up +0.44% this morning as U.S. Treasury yields slipped from decade highs, while investors braced for a new round of economic data as well as an earnings...

NQZ23 : 16,530.23s (-0.07%)
CTAS : 190.33 (-7.09%)
AAPL : 188.38 (-7.29%)
GOOGL : 145.60 (-3.40%)
AMZN : 171.00 (-4.15%)
DKNG : 31.67 (-2.25%)
MU : 64.72 (-12.94%)
PAYX : 143.32 (-6.65%)
JEF : 43.14 (-10.03%)
HMB.S.DX : 128.250 (-1.02%)
COST : 916.48 (-5.23%)
CHPT : 0.5765 (+1.12%)
Cardiff Oncology Announces Positive Clinical Data in Pancreatic Cancer and Small Cell Lung Cancer, including Single-Agent Activity from Onvansertib Monotherapy

Pancreatic Cancer Program - Pancreatic cancer Phase 2 trial of onvansertib + SoC in the second-line setting demonstrated greater efficacy vs. historical...

CRDF : 2.75 (-4.18%)

Business Summary

Cardiff Oncology Inc. is a clinical-stage biotechnology company. It engages in developing treatment for cancer patients. The company's product pipeline consists of a Phase 1b/2 study of onvansertib in combination with FOLFIRI/Avastin(R) in KRAS-mutated metastatic colorectal cancer; a Phase 2 study of...

See More

Key Turning Points

3rd Resistance Point 3.04
2nd Resistance Point 2.93
1st Resistance Point 2.84
Last Price 2.75
1st Support Level 2.64
2nd Support Level 2.53
3rd Support Level 2.44

See More

52-Week High 6.35
Fibonacci 61.8% 4.69
Fibonacci 50% 4.18
Fibonacci 38.2% 3.67
Last Price 2.75
52-Week Low 2.01

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
Trader's Cheat Sheet: Your Secret Weapon for Smarter Trades